Therapeutically targeting the major genetic risk factor of Alzheimer’s disease [ 2018 - ]

Research Grant

Researchers: Dr Scott Ayton (Principal investigator) ,  Dr Marcus Conrad

Brief description The second greatest risk factor for Alzheimer’s disease (after age) is genetic variation in a protein called APOE, however it is unknown why APOE increases the risk of disease. We have new clinical and laboratory evidence that APOE incresase risk of Alzheimer’s disease by manipulating iron pathways in the brain. We plan to examine these pathways and apply a new theraputic we have developed that targets these pathways in animal models of Alzheimer’s disease.

Funding Amount $522,751.00

Funding Scheme Project Grants

Notes Standard Project Grant